Homocysteine, folate deficiency, and Parkinson's disease.
Folate deficiency sensitizes mice to dopaminergic neurodegeneration and motor dysfunction caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Additional experiments indicate that this effect of folate deficiency may be mediated by homocysteine. These findings suggest that folate deficiency and hyperhomocysteinemia are risk factors for Parkinson's disease.
Miller
Joshua W
JW
University of California, Davis, Medical Center, Department of Medical Pathology, Research Building III, Room 3200A, 4645 Second Ave, Sacramento, CA 95817, USA.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D004298:Dopamine / Q000378:metabolism; D005494:Folic Acid Deficiency / Q000150:complications*; D006710:Homocysteine / Q000097:blood; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications*; D051379:Mice; D010300:Parkinson Disease / Q000209:etiology*; D012307:Risk Factors
D006710:Homocysteine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine